Matinas BioPharma Inc.

AI Score

0

Unlock

0.57
-0.01 (-1.69%)
At close: Feb 06, 2025, 3:08 PM
undefined%
Bid 0.56
Market Cap 2.92M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -4.74
PE Ratio (ttm) -0.12
Forward PE n/a
Analyst Hold
Ask 0.58
Volume 28,311
Avg. Volume (20D) 496,036
Open 0.59
Previous Close 0.58
Day's Range 0.56 - 0.59
52-Week Range 0.48 - 21.50
Beta undefined

About MTNB

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a presc...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 21, 2014
Employees 32
Stock Exchange AMEX
Ticker Symbol MTNB

Analyst Forecast

According to 1 analyst ratings, the average rating for MTNB stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts
3 months ago
-67.88%
Matinas Biopharma shares are trading lower after t... Unlock content with Pro Subscription